Cat. #157676
RMA.Trh4 cell line
Cat. #: 157676
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 8-10 weeks
Organism: Mouse
Tissue: Lymphatic Tissue
Disease: Cancer
Model: Tumour line
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Thorbald Van Hall
Institute: Leiden University and Leiden University Medical Center; Stichting Oncode Institute
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: RMA.Trh4 cell line
- Cancer: Blood cancer
- Cancers detailed: Mouse Leukemia
- Research fields: Cancer
- Tool sub type: Continuous
- Parental cell: RMA
- Organism: Mouse
- Tissue: Lymphatic Tissue
- Disease: Cancer
- Model: Tumour line
- Description: This cell line provides a model to help to understand T-cell recognition through Trh4 expression. ER-resident ceramide synthase Trh4 is a prototypic example of a neo-antigen selectively presented by cells through various pathways. RMA cells have their TAP chain intact and the Trh4 peptide is only presented on cells with impaired TAP function through the classical MHC I pathway. This cell line over-expresses endogenous Trh4 and provides a key tool to help understand presentation of Trh4 to antigen recognition though other pathways.
- Biosafety level: 1
- Recommended controls: RMA-S.Trh4 cells
- Cellosaurus id: CVCL_J385
Target Details
- Target: Trh4
Handling
- Format: Frozen
- Growth medium: Retroviral transduction of the mouse Trh4 gene in an IRES-GFP construct
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
- Storage conditions: Liquid Nitrogen
- Mycoplasma free: Yes
References
- Oliveira et al. 2011. Eur J Immunol. 41(11):3114-24. PMID: 21898382.
